Skip to main content
. 2021 Jun 24;13(7):940. doi: 10.3390/pharmaceutics13070940

Table 2.

Bacteria membrane-based nanoparticles in cancer treatment.

Membrane Source Cancer Type Membrane Type Cargo Efficacy Ref.
Salmonella B16F10 and 4T1
tumors
OMV Tegafur@F127 nanomicelles
  • (1)

    Surface is modified with RGD to preferentially accumulate in tumor tissues

  • (2)

    Combination of chemotherapy and immunotherapy

[71]
Ehrlich ascites carcinoma (EAC) OMV Paclitaxel
  • (1)

    Passive accumulation in tumor tissues through the EPR effect

  • (2)

    Combination of chemotherapy and immunotherapy

[72]
Escherichia coli Human lung carcinoma A459 cells Protoplast-derived nanovesicles Doxorubicin
  • (1)

    Bioengineered with high expression of the epidermal growth factor to target the tumor

  • (2)

    Alleviation of systemic toxicity of the chemotherapeutic agent

[73]
B16F10 tumor DMV Doxorubicin
  • (1)

    Bioengineered with high expression of RGD motifs to target the tumor

  • (2)

    Targeting of the neutrophils or monocytes that mediate transportation towards the tumor

[74]
HER2-overexpressing HCC1954 cells OMV siRNA
  • (1)

    Targeting of tumor tissues via the EPR effect

  • (2)

    Avoidance of gene leakage and protection from degradation

[75]
CT26 and 4T1 tumors OMV ICG
  • (1)

    Surface is functionalized with a calcium phosphate shell to respond to the acidic environment of the tumor

  • (2)

    Combination of photothermal therapy and immunotherapy

[68]
B16F10 tumor OMV ICG
  • (1)

    Transdermal nanoplatform against melanoma

  • (2)

    Combination of photothermal, photodynamic therapy, and immunotherapy

[76]
TC-1 and B16F10 tumors OMV BFGF
  • (1)

    Use as a cancer vaccine

  • (2)

    Induction of production of the antibodies that target tumor angiogenesis

[77]

Abbreviations: RGD: amino sequence of arginine, glycine, and aspartate; ICG: indocyanine green; BFGF: basic fibroblast growth factor.